Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2018/04/013431
CTRI/2018/04/013431
Active, not recruiting
Phase 2

A Clinical Comparative study to evaluate the safety and efficacy of Himfera capsules in the Management of Iron Deficiency Anaemia - HimC

The Himalaya Drug Company0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
The Himalaya Drug Company
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Subjects of both sexes in the age group of 18\-70 years with Hemoglobin \<11gm/dL.
  • •2\.Subjects who have clinical symptoms such as pale skin colour, extreme fatigue, irritability, weakness, brittle nails, palpitation, headache, loss of appetite.
  • •3\.Subjective improvement in quality of life in subjects with Iron deficiency anaemic.
  • •4\.Subjects willing to give written informed consent.
  • •5\.Subjects who have not participated in similar kind of study in last 3 months.

Exclusion Criteria

  • •Subjects with hemoglobin concentration \< 6 gm/dl, patients of thalassaemia, sickle cell anemia, aplastic anemia, haemolytic anemia, lead poisoning, sideroblastic anaemia, malignancies, congenital.
  • •Blood hemoglobin level \< 5 gm/dl during the course of any treatment, any other acute illness, severe untoward effect.
  • •Absence of iron binding protein, hereditory spherocytosis and any association of severe complication.
  • •Pregnant \& lactating women.
  • •Not willing to sign informed consent form.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Himferra Capsules for AnemiaHealth Condition 1: null- individuals with Iron Deficiency Anaemia (IDA)
CTRI/2017/12/010959The Himalaya Drug Company40
Completed
Not Applicable
Monofocal Extended Depth of Focus Intraocular Lens for the Correction of AphakiaHealth Condition 1: H268- Other specified cataract
CTRI/2020/09/027637Advanced Vision Science Inc
Completed
Not Applicable
Open-label, multicenter clinical study to evaluate the safety and efficacy of ULKOX® OLE vs SoC (e.g., cicatridinum ointment, ointment for anal fissures) in adult patients diagnosed with anal fissures
ISRCTN40732544oventure S.L.42
Recruiting
Phase 2
A clinical Trial on Oligospermia to evaluate the Siddha interventio
CTRI/2022/09/046073Central Council for Research in Siddha Ministry of AYUSH
Completed
Not Applicable
A clinical evaluation to compare the safety, efficacy and performance of ABSORB everolimus eluting bioresorbable vascular scaffold against XIENCE PRIME everolimus eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesionsangina pectorisischemic heart disease10011082
NL-OMON39935Abbott Vascular International BVBA150